Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: Rationale for the treatment of patients with infliximab

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages

  Dagna, Lorenzo ^a   Corti, Angelo ^b   Langheim, Silvia ^b   Guglielmi, Barbara ^a   De Cobelli, Francesco ^a   Doglioni, Claudio ^a   Fragasso, Gabriele ^b   Sabbadini, Maria Grazia ^a   Ferrarini, Marina ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANGIOPLASTY; ARTICLE; BONE BIOPSY; BONE SCINTISCANNING; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERDHEIM CHESTER DISEASE; HEART FAILURE; HEART FUNCTION; HEART TAMPONADE; HUMAN; INFLAMMATION; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; MALE; MEDICAL HISTORY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RECURRENT DISEASE; THORACOTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANTIBODIES, MONOCLONAL; CHEMOKINE CCL11; CYTOKINES; ERDHEIM-CHESTER DISEASE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867083505     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.9911     Document Type: Article

References (28)

1. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al: Erdheim-Chester disease: Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 75:157-169, 1996 (Pubitemid 26159212)
2. Haroche J, Amoura Z, Touraine P, et al: Bilateral adrenal infiltration in Erdheim-Chester disease: Report of seven cases and literature review. J Clin Endocrinol Metab 92:2007-2012, 2007 (Pubitemid 46997091)
3. Devouassoux G, Lantuejoul S, Chatelain P, et al: Erdheim-Chester disease: A primary macrophage cell disorder. Am J Respir Crit Care Med 157:650-653, 1998 (Pubitemid 28090562)
4. Braiteh F, Boxrud C, Esmaeli B, et al: Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 106:2992-2994, 2005 (Pubitemid 41565890)
5. Haroche J, Amoura Z, Trad SG, et al: Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: Results in eight patients. Arthritis Rheum 54:3330-3336, 2006 (Pubitemid 44622105)
6. Haroche J, Amoura Z, Dion E, et al: Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: Report of 6 new cases and a literature review. Medicine (Baltimore) 83:371-392, 2004 (Pubitemid 39541113)
7. Aouba A, Georgin-Lavialle S, Pagnoux C, et al: Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 116:4070-4076, 2010
8. Stoppacciaro A, Ferrarini M, Salmaggi C, et al: Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesis. Arthritis Rheum 54:4018-4022, 2006 (Pubitemid 44955906)
9. Dagna L, Girlanda S, Langheim S, et al: Erdheim-Chester disease: Report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 49:1203-1206, 2010
10. Yarilina A, Park-Min KH, Antoniv T, et al: TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 9:378-387, 2008 (Pubitemid 351405107)
11. Ferrari R, Bachetti T, Confortini R, et al: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92:1479-1486, 1995
12. Tracey D, Klareskog L, Sasso EH, et al: Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117:244-279, 2008
13. Balink H, Hemmelder MH, de Graaf W, et al: Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol 29:e470-e472, 2011
14. Mekinian A, Neel A, Sibilia J, et al: Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford), 882-886, 2012
15. Bendtzen K, Geborek P, Svenson M, et al: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 54:3782-3789, 2006 (Pubitemid 44955878)
16. Taylor PC, Feldmann M: Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5:578-582, 2009
17. Haroche J, Amoura Z, Charlotte F, et al: Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 111:5413-5415, 2008
18. Myra C, Sloper L, Tighe PJ, et al: Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 88:844-847, 2004 (Pubitemid 38725610)
19. Janku F, Amin HM, Yang D, et al: Response of histiocytoses to imatinib mesylate: Fire to ashes. J Clin Oncol 28:e633-e636, 2010
20. Monti L, Haroche J, Sciarra A, et al: Interferon-alpha in cardiac Erdheim-Chester disease. J Am Coll Cardiol 58:2695, 2011
21. Arnaud L, Hervier B, Néel A, et al: CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood 117:2778-2782, 2011
22. Aderka D, Engelmann H, Maor Y, et al: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329, 1992
23. Pennica D, Lam VT, Mize NK, et al: Biochemical properties of the 75-kDa tumor necrosis factor receptor: Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem 267:21172-21178, 1992
24. Karlson EW, Chibnik LB, Tworoger SS, et al: Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 60:641-652, 2009
25. Gregorc V, Spreafico A, Floriani I, et al: Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer 110:845-853, 2007 (Pubitemid 47257663)
26. Mossetti G, Rendina D, Numis FG, et al: Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol 21:232-236, 2003 (Pubitemid 36519571)
27. Arnaud L, Gorochov G, Charlotte F, et al: Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients. Blood 117:2783-2790, 2011
28. Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712, 2006